
    
      Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, 12-AVR-131, or
      17-AVP-786-305.

      Participants will be enrolled in the study for approximately 56 weeks (participants who have
      a follow-up visit 3 months after the last dose of treatment will be enrolled for
      approximately 64 weeks).

      Approximately 1000 participants will be enrolled at approximately 250 centers globally.

      All participants enrolled will receive AVP-786; the treatment dose assigned will be masked to
      the participant, investigator, study staff, and the sponsor.
    
  